» Articles » PMID: 11126392

Acetyl-L-carnitine Physical-chemical, Metabolic, and Therapeutic Properties: Relevance for Its Mode of Action in Alzheimer's Disease and Geriatric Depression

Overview
Journal Mol Psychiatry
Date 2000 Dec 29
PMID 11126392
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Acetyl-L-carnitine (ALCAR) contains carnitine and acetyl moieties, both of which have neurobiological properties. Carnitine is important in the beta-oxidation of fatty acids and the acetyl moiety can be used to maintain acetyl-CoA levels. Other reported neurobiological effects of ALCAR include modulation of: (1) brain energy and phospholipid metabolism; (2) cellular macromolecules, including neurotrophic factors and neurohormones; (3) synaptic morphology; and (4) synaptic transmission of multiple neurotransmitters. Potential molecular mechanisms of ALCAR activity include: (1) acetylation of -NH2 and -OH functional groups in amino acids and N terminal amino acids in peptides and proteins resulting in modification of their structure, dynamics, function and turnover; and (2) acting as a molecular chaperone to larger molecules resulting in a change in the structure, molecular dynamics, and function of the larger molecule. ALCAR is reported in double-blind controlled studies to have beneficial effects in major depressive disorders and Alzheimer's disease (AD), both of which are highly prevalent in the geriatric population.

Citing Articles

Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.

Montanari S, Jansen R, Schranner D, Kastenmuller G, Arnold M, Janiri D Transl Psychiatry. 2025; 15(1):65.

PMID: 39988721 PMC: 11847943. DOI: 10.1038/s41398-025-03274-x.


Sex differences in mitochondrial free-carnitine levels in subjects at-risk and with Alzheimer's disease in two independent study cohorts.

Bigio B, Lima-Filho R, Barnhill O, Sudo F, Drummond C, Assuncao N Mol Psychiatry. 2025; .

PMID: 39774493 DOI: 10.1038/s41380-024-02862-5.


Circulating medium- and long-chain acylcarnitines are associated with plasma P-tau181 in cognitively normal older adults.

Sharmin T, Chatterjee P, Doecke J, Ashton N, Huynh K, Pedrini S J Neurochem. 2024; 169(2).

PMID: 39473263 PMC: 11808462. DOI: 10.1111/jnc.16244.


Evaluating the causal relationship of Levo-carnitine and risk of schizophrenia: a bidirectional two-sample mendelian randomization study.

Qiu H, Zhong Z, Wu T, Hu H, Zhou M, Feng Z BMC Psychiatry. 2024; 24(1):720.

PMID: 39438849 PMC: 11515733. DOI: 10.1186/s12888-024-06177-1.


Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.

Milaneschi Y, Montanari S, Jansen R, Schranner D, Kastenmuller G, Arnold M Res Sq. 2024; .

PMID: 39149483 PMC: 11326352. DOI: 10.21203/rs.3.rs-4638158/v1.